Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Medical
EPIC: POSC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Positron Corporation
www.positron.com

Positron Corporation offers innovative solutions through the production and distribution of molecular
imaging systems and radiopharmaceutical technologies.

Full Positron Corporation profile here
Pdf

Positron agrees to produce strontium-82 with Arronax

18th Nov 2011, 10:51 am by Olivia D'Orazio
Positron agrees to produce strontium-82 with Arronax

Molecular imaging company Positron (OTCBB:POSC) said Friday that, through its soon-to-be subsidiary, Manhattan Isotope Technology (MIT), it has entered into a memorandum of understanding with Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic (Arronax), to collaborate on the production of strontium-82.

Positron uses strontium-82, a synthetic radioisotope, in its positron emission tomography (PET) scanning machines, which help diagnose heart disease in about 400 patients each day.

MIT president, Jason Kitten said: "Working with the high caliber scientists at ARRONAX and their cutting-edge high power cyclotron is truly a tremendous growth opportunity for [strontium-82] supply.

"We fully expect that the collaboration of Arronax and MIT will expand the global supply of [strontium-82]; a supply that is very limited and in great demand by the medical community."

Located in Nantes, France, Arronax operates a 70 million electric volt (MeV) cyclotron, and associated support facilities. A cyclotron creates a strong magnetic field, which causes a charged particle to accelerate and re-enter high-voltages at high speeds. The machine has many applications, including the production of the synthetic radioisotope, strontium-82.

Positron said the Arronax facility is only one of a small number in the world with the requisite proton beam characteristics required for strontium-82 production.

Currently, the U.S. Department of Energy is the only American producer of the synthetic isotope.

Under the terms of the agreement, Positron and Arronax will also collaborate on the production of other high-energy radioisotopes that have medical applications, like geranium-68.

Earlier this month, Positron announced that it would acquire MIT, though it did not disclose the details of the transaction. The acquisition is expected to close in early 2012, and is subject to regulatory approvals.

Shares of the Texas-based Positron rose 3.16 percent on Friday, to $0.0163 as of 10:04 am ET.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.